22 citations
,
October 2001 in “Biochemical Pharmacology” This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.
February 2017 in “대한피부과학회지” This case report describes a 52-year-old man with androgenic alopecia who experienced improvement after adding low-dose dutasteride to long-term finasteride treatment when the initial therapy's effectiveness waned.
3 citations
,
January 2015 in “Journal of drug assessment” This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.
January 2024 in “Journal of the Egyptian Women's Dermatologic Society (Print)” This study found that combining minoxidil 0.1% and dutasteride 0.01% applied topically after microneedling was significantly more effective than using dutasteride alone with microneedling in improving female pattern hair loss in 40 female patients.
2 citations
,
April 2016 in “Journal of The American Academy of Dermatology” This study found that dutasteride was more effective than finasteride in increasing total and thick hair count and reducing thin hair count in men with AGA, with both drugs having similar side effect profiles.
52 citations
,
February 2006 in “Current pharmaceutical design” This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.
46 citations
,
March 2001 in “Journal of endocrinological investigation” This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.
11 citations
,
February 2016 in “Current Medicinal Chemistry” This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.
3 citations
,
May 2020 in “Journal of The Korean Medical Association” This review discusses treatment options for androgenetic alopecia, with a focus on the better efficacy of oral finasteride and dutasteride over topical minoxidil for male pattern hair loss, but it reports no new clinical results.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.
March 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
2 citations
,
April 2024 in “Journal of Clinical Psychopharmacology” In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.
This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.
September 2015 in “Korean Journal of Clinical Pharmacy” In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.
September 2025 in “JAAD International” In this study, twice-weekly and thrice-weekly dutasteride improved hair growth and were well-tolerated, although thrice-weekly dosing did not significantly outperform finasteride 1 mg daily for increasing hair count.
June 2025 in “Journal of Cosmetic Dermatology” This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.
2 citations
,
March 2016 in “The Journal of Urology” This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.
January 2026 in “Journal of Dermatological Treatment” The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.
4 citations
,
July 2021 in “Journal of Dermatological Treatment” This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.
June 2007 in “Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii” This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.
19 citations
,
January 2016 in “Annals of Dermatology” This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.
15 citations
,
January 2018 in “Acta dermato-venereologica” This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.
September 2015 in “한국임상약학회지” In this study, both the topical minoxidil 7%/dutasteride 0.5 mg and topical minoxidil 7%/finasteride 1 mg treatments for androgenetic alopecia showed high effectiveness, but the dutasteride combination was associated with greater efficacy and more adverse effects.
33 citations
,
August 2016 in “Indian Journal of Dermatology, Venereology and Leprology” In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This review discusses a study on the efficacy and safety of different doses of dutasteride compared to placebo and finasteride in treating men with androgenetic alopecia and reports no new results.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.
July 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride do not significantly change beard thickness in men.
April 2024 in “Dermatology reports” This systematic review concluded that dutasteride was more effective than finasteride in increasing hair count for treating androgenetic alopecia in both males and females, with comparable side effects.
July 2011 in “Springer eBooks” This review discusses both conventional and new pharmaceutical treatments for hair loss, as well as various natural and herbal remedies, but reports no new clinical results.